SAS Output

23-JAN-2018 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1320-Adv, BRAF mut, Inter v Contin 1 Y 1 Lead-in Continuous Dosing 280 194 65 31 18 4 1 09/19/2014 230 102
            194 65 31 18 4 1      
 
    2 Y 2 Continuous Dosing 280 81 28 16 9 5 1 09/19/2014    
        3 Intermittent Dosing   78 25 14 7 5 1      
            159 53 30 16 10 2      
 
  S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 77 5 5 4 2 0 0 02/06/2017 76 33
            5 5 4 2 0 0      
 
  S1616-MELAN, Adv, Ipilimumab ± Nivolumab 1 Y 1 Ipilimumab 94 1 1 1 1 0 0 10/23/2017   60
        2 Nivolumab + Ipilimumab   4 4 4 3 2 1      
            5 5 5 4 2 1      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   24 11 8 2 0 0 11/03/2015 353 147
            24 11 8 2 0 0      
 
    2 E Total Registrations   5 2 1 0 0 0 11/03/2015    
            5 2 1 0 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim 1 E Total Registrations   36 21 0 0 0 0 03/25/2016 310 122
            36 21 0 0 0 0      
 
No E3612-MELAN,Adv Ipilimumab±Bevacizumab 1 E Total Registrations   6 1 1 0 0 0 02/16/2015 115 41
            6 1 1 0 0 0      
 

23-JAN-2018 6:10

MELAN Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1607 MELAN, Adv, T-VEC, MK-3475 1 Registration 02-Oct-17